3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Glioblastoma
47
Brain Neoplasms
24
Central Nervous System Neoplasms
22
Astrocytoma
16
Glioma
15
Medulloblastoma
11
Neoplasms
8
Oligodendroglioma
7
Lymphoma
7
Recurrence
6
Gliosarcoma
6
Spinal Cord Neoplasms
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma, AIDS-Related
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Ependymoma
2
Burkitt Lymphoma
2
Uveal Melanoma
1
Solid Tumor
1
Sarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Optic Nerve Glioma
1
Newly Diagnosed High Grade Glioma
1
Neuroectodermal Tumors, Primitive
1
Neuroectodermal Tumors
1
Interventions
Vincristine
2
Temozolomide
2
Oncolytic Virotherapy
2
repotrectinib
1
pralsetinib
1
pembrolizumab
1
pamiparib
1
interferon gamma-1b
1
cixutumumab
1
Vorinostat
1
Valproic Acid
1
Thiotepa
1
Sunitinib
1
Radiotherapy
1
Radiation
1
Peripheral Blood Stem Cell Transplantation
1
ONC206
1
Melphalan
1
Maintenance Chemotherapy
1
Lomustine
1
Interleukin-12
1
Interferon-gamma
1
Immunotherapy
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Etoposide
1
Erlotinib Hydrochloride
1
Doxorubicin
1
Cyclophosphamide
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neuroectodermal Tumors
×
Lomustine
×
Clear all
NCT01614132
2020-03-31
NOA-07
University of Regensburg
Phase 1/2
Completed
33 enrolled